Literature DB >> 11382638

Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk?

A C Moll1, S M Imhof, A Y Schouten-Van Meeteren, D J Kuik, P Hofman, M Boers.   

Abstract

OBJECTIVE: The aim of this study is to evaluate the influence of age at external beam irradiation (EBRT) on the occurrence of second primary tumors (SPTs) inside and outside the irradiation field in hereditary retinoblastoma patients.
DESIGN: Cross-sectional study. PARTICIPANTS: The study included 263 hereditary retinoblastoma patients born in The Netherlands between 1945 and 1997.
METHODS: A national register-based follow-up cohort study was performed on hereditary retinoblastoma patients. Information on therapy, age at irradiation, and location of SPT was obtained from the register. The Kaplan-Meier method calculated cumulative incidences of SPT in three subgroups: irradiation before (early EBRT) and after 12 months of age (late EBRT), and no irradiation. The Mantel-Cox method determined the statistical significance of differences between the cumulative incidence curves. MAIN OUTCOME MEASURES: Development of SPT inside and outside a precisely defined irradiation field in relation to age at irradiation. Our definition excluded pineoblastoma as SPT, because they constitute part of a trilateral retinoblastoma; in addition, they lie outside the field of irradiation.
RESULTS: The cumulative incidence of SPT at the age of 25 years was 22% (95% confidence intervals 13%-34%) in the early EBRT group, 3% (0%-14%) in the late EBRT group, and 5% (1%-16%) in the nonirradiated group (Mantel-Cox overall: P = 0.001; between early and late EBRT, P = 0.04). However, in early irradiated patients, the incidence of SPTs inside and outside the irradiation field was similar (11%), and the difference between early and late EBRT in incidence of SPT inside the field of irradiation was less prominent than overall (11% vs. 3%: P = 0.37). Sensitivity analysis showed the results depended on the way SPT, irradiation field, and, especially, pineoblastomas are defined.
CONCLUSIONS: Hereditary retinoblastoma confers an increased risk for the development of SPT, especially in patients treated with EBRT before the age of 12 months. However, the presence of similar numbers of SPTs inside and outside the irradiation field suggests that irradiation is not the cause. In other words, this study does not show an age effect on radiation-related risk. Rather, early EBRT is probably a marker for other risk factors of SPT.

Entities:  

Mesh:

Year:  2001        PMID: 11382638     DOI: 10.1016/s0161-6420(01)00562-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  29 in total

1.  New RB1 oncogenic mutations and intronic polymorphisms in Serbian retinoblastoma patients: genetic counseling implications.

Authors:  Milica Kontic; Iciar Palacios; Ángelo Gámez; Isabel Camino; Zoran Latkovic; Dejan Rasic; Vera Krstic; Vera Bunjevacki; Javier Alonso; Ángel Pestaña
Journal:  J Hum Genet       Date:  2006-09-14       Impact factor: 3.172

2.  Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy.

Authors:  Roshan V Sethi; Helen A Shih; Beow Y Yeap; Kent W Mouw; Robert Petersen; David Y Kim; John E Munzenrider; Eric Grabowski; Carlos Rodriguez-Galindo; Torunn I Yock; Nancy J Tarbell; Karen J Marcus; Shizuo Mukai; Shannon M MacDonald
Journal:  Cancer       Date:  2013-10-02       Impact factor: 6.860

3.  Genetic screening in Iranian patients with retinoblastoma.

Authors:  K Shahraki; A Ahani; P Sharma; M Faranoush; G Bahoush; I Torktaz; W A Gahl; M Naseripour; B Behnam
Journal:  Eye (Lond)       Date:  2016-12-16       Impact factor: 3.775

Review 4.  Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma.

Authors:  Emily S Tonorezos; Danielle Novetsky Friedman; Dana Barnea; Machteld I Bosscha; Guillermo Chantada; Charlotte J Dommering; Pim de Graaf; Ira J Dunkel; Armida W M Fabius; Jasmine H Francis; Mary-Louise C Greer; Ruth A Kleinerman; Wijnanda A Kors; Suzanne Laughlin; Annette C Moll; Lindsay M Morton; Petra Temming; Margaret A Tucker; Flora E van Leeuwen; Michael F Walsh; Kevin C Oeffinger; David H Abramson
Journal:  Ophthalmology       Date:  2020-05-15       Impact factor: 12.079

Review 5.  Management of retinoblastoma in children: current status.

Authors:  Guillermo Chantada; Paula Schaiquevich
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

6.  Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.

Authors:  Jeannette R Wong; Lindsay M Morton; Margaret A Tucker; David H Abramson; Johanna M Seddon; Joshua N Sampson; Ruth A Kleinerman
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

Review 7.  Current treatment and management of retinoblastoma.

Authors:  Dan S Gombos; And Patricia Chevez-Barrios
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

8.  Differential diagnosis of leukocoria and strabismus, first presenting signs of retinoblastoma.

Authors:  Aubin Balmer; Francis Munier
Journal:  Clin Ophthalmol       Date:  2007-12

9.  Cause-specific mortality in long-term survivors of retinoblastoma.

Authors:  Chu-Ling Yu; Margaret A Tucker; David H Abramson; Kyoji Furukawa; Johanna M Seddon; Marilyn Stovall; Joseph F Fraumeni; Ruth A Kleinerman
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

Review 10.  Current management strategies for intraocular retinoblastoma.

Authors:  Jonathan W Kim; David H Abramson; Ira J Dunkel
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.